JavaScript is disabled in your browser. Please enable JavaScript to view this website.

AKR1C4

Function

Cytosolic aldo-keto reductase that catalyzes the NADH and NADPH-dependent reduction of ketosteroids to hydroxysteroids. Liver specific enzyme that acts as an NAD(P)(H)-dependent 3-, 17- and 20-ketosteroid reductase on the steroid nucleus and side chain (PubMed:10634139, PubMed:10998348, PubMed:11158055, PubMed:14672942, PubMed:1530633, PubMed:19218247, PubMed:7650035). Displays the ability to catalyze both oxidation and reduction in vitro, but most probably acts as a reductase in vivo since the oxidase activity measured in vitro is inhibited by physiological concentration of NADPH (PubMed:14672942). Acts preferentially as a 3-alpha-hydroxysteroid dehydrogenase (HSD) with a subsidiary 3-beta-HSD activity (PubMed:14672942). Catalyzes efficiently the transformation of the potent androgen 5-alpha-dihydrotestosterone (5alpha-DHT or 17beta-hydroxy-5alpha-androstan-3-one) into the less active form, 5-alpha-androstan-3-alpha,17-beta-diol (3-alpha-diol) (PubMed:10998348, PubMed:11158055, PubMed:14672942). Catalyzes the reduction of estrone into 17beta-estradiol but with low efficiency (PubMed:14672942). Metabolizes a broad spectrum of natural and synthetic therapeutic steroid and plays an important role in metabolism of androgens, estrogens, progestereone and conjugated steroids (PubMed:10998348, PubMed:14672942, PubMed:19218247). Catalyzes the biotransformation of the pesticide chlordecone (kepone) to its corresponding alcohol leading to increased biliary excretion of the pesticide and concomitant reduction of its neurotoxicity since bile is the major excretory route (PubMed:2427522).

Involvement in disease

46,XY sex reversal 8

SRXY8

A disorder of sex development. Affected individuals have a 46,XY karyotype but present as phenotypically normal females.

None

The gene represented in this entry may act as a disease modifier. A splicing mutation resulting in loss of AKR1C4 exon 2 has been found in affected individuals carrying a causative mutation in AKR1C2 (PubMed:21802064). These patients manifest a more severe disease phenotype than individuals only carrying mutations in AKR1C2.

Pathway

Steroid metabolism.

Post-translational modifications

The N-terminus is blocked.

Sequence Similarities

Belongs to the aldo/keto reductase family.

Tissue Specificity

Liver specific.

Cellular localization

Alternative names

CHDR, AKR1C4, Aldo-keto reductase family 1 member C4, 3-alpha-hydroxysteroid dehydrogenase type I, 3alpha-hydroxysteroid 3-dehydrogenase, Chlordecone reductase, Dihydrodiol dehydrogenase 4, HAKRA, 3-alpha-HSD1, CDR, DD-4, DD4

swissprot:P17516 omim:600451 entrezGene:1109